New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
07:23 EDTAUXLUBS calls Auxilium a 'sleeper pick' for 2014
UBS believes investors are overlooking Auxilium's highly leveraged business model which will be driven by strong Xiaflex, Stendra, and Testopel growth, and stabilizing Testim. The firm expects operating margins to move towards 30% by 2016-17 from approximately 10% in 2013 and a pathway for 30% stock return performance over the next year. Shares are Buy rated with a $30 price target, up from $23.
News For AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:13 EDTAUXLBioSpecifics announces FDA approval of sBLA for XIAFLEX
Subscribe for More Information
October 20, 2014
17:33 EDTAUXLAuxilium announces XIAFLEX approved for treatment of up to two DC joints
Subscribe for More Information
October 13, 2014
06:41 EDTAUXLEndo upgraded to Hold from Sell at Cantor
Subscribe for More Information
October 10, 2014
11:18 EDTAUXLOptions with decreasing implied volatility
Subscribe for More Information
10:01 EDTAUXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:35 EDTAUXLAuxilium downgraded to Neutral from Buy at MKM Partners
Subscribe for More Information
05:50 EDTAUXLEndo upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
05:47 EDTAUXLAuxilium downgraded to Neutral from Buy at Mizuho
Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use